The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

Aladul, Mohammed I.; Fitzpatrick, Raymond W.; Chapman, Stephen R.

doi:10.1016/j.sapharm.2018.05.009

All Outputs (3)

Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database (2025)
Journal Article
Chan, S. H. Y., Fitzpatrick, R. W., Layton, D., Webley, S., & Salek, S. (in press). Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database. Cancers, 17(2), 1-17. https://doi.org/10.3390/cancers17020311

Background: The accelerated development of novel cancer therapies necessitates a thorough understanding of the associated cardiotoxicity profiles, due to their significant implications for the long-term health and quality of life of cancer survivors.... Read More about Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database.

Investigation of the hospital pharmacy profession in Europe (2024)
Journal Article
Kuruc Poje, D., Fitzpatrick, R. W., Stevens, C., Machin, C., Underhill, J., Horák, P., …Marzal Lopez, G. (2024). Investigation of the hospital pharmacy profession in Europe. European Journal of Hospital Pharmacy, https://doi.org/10.1136/ejhpharm-2023-004066

Objective: From 1995, the European Association of Hospital Pharmacists (EAHP) has regularly investigated the progress of the hospital pharmacy profession in Europe, and identified key barriers and drivers of this. The most recent ‘Investigation of th... Read More about Investigation of the hospital pharmacy profession in Europe.

The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis (2018)
Journal Article
Aladul, M. I., Fitzpatrick, R. W., & Chapman, S. R. (2019). The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Research in Social and Administrative Pharmacy, 15(3), 310-317. https://doi.org/10.1016/j.sapharm.2018.05.009

Background:
The approval of new biosimilars of infliximab, etanercept and adalimumab by the European Medicines Agency is expected to produce further cost savings to the healthcare system budget.

Objectives:
This study aimed to estimate the budg... Read More about The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.